Effectiveness and tolerability of sublingual ketamine treatment
Major Depressive Disorder | Suicidal Ideation | Depressive Symptoms | Treatment ResponseAbout one third of patients with depression fail to respond to standard treatments and are considered treatment resistant (TRD). Ketamine has emerged as a potent therapy for TRD. Despite its benefits, there is limited data about the effectiveness and tolerability of sublingual ketamine treatment. Sublingual ketamine, unlike the more popular intravenous ketamine treatment, has several advantages including ease of use, cost-effectiveness, and the possibility of broader dissemination, including home-based administration. Therefore, this study aims to support the available evidence, by observing the effects of Sublingual ketamine in real world clinical practice.
null
Participation Requirements
-
Sex:
Any -
Eligible Ages:
18 to 65
Participation Criteria
Inclusion Criteria:
Patients 18-65 years old with unipolar or bipolar TRD (TRD – baseline MADRS score = 20 and experienced at least 2 failed standard of care treatment trials of adequate dose and duration) at Misericordia Hospital will be eligible for the study. In our research center (Misericordia Hospital), TRD patients are referred to our service as outpatients by other clinicians in Edmonton catchment area.
Exclusion Criteria:
Exclusion criteria includes: patients not medically eligible for sublingual ketamine treatment. This includes reporting any active substance abuse, psychosis, serious uncontrolled medical condition, previous negative reaction to ketamine or esketamine, currently pregnant or breastfeeding
Study Location
University of Alberta
University of AlbertaEdmonton, Alberta
Canada
Contact Study Team
- Study Sponsored By
- University of Alberta
- Participants Required
- More Information
- Study ID:
Pro00092874